
Fotis Nikolos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6521521/publications.pdf Version: 2024-02-01



| # | Article | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Intercepting IRE1 kinaseâ€FMRP signaling prevents atherosclerosis progression. EMBO Molecular Medicine, 2022, 14, e15344. | 6.9 | 10 |
| 2 | Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. Nature Communications, 2022, 13, 1487. | 12.8 | 17 |
| 3 | Inhibitory DAMPs in immunogenic cell death and its clinical implications. Cell Stress, 2021, 5, 52-54. | 3.2 | 6 |
| 4 | Estrogen Receptor Î ² -Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. Cancer Research, 2021, 81, 2399-2414. | 0.9 | 7 |
| 5 | Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nature Communications, 2020, 11, 6299. | 12.8 | 128 |
| 6 | Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. Nature Communications, 2019, 10, 2131. | 12.8 | 27 |
| 7 | GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocrine-Related Cancer, 2018, 25, 453-469. | 3.1 | 48 |
| 8 | Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas. Journal of the National Cancer Institute, 2018, 110, 448-459. | 6.3 | 112 |
| 9 | ERÎ ² Sensitizes NSCLC to Chemotherapy by Regulating DNA Damage Response. Molecular Cancer Research, 2018, 16, 233-242. | 3.4 | 14 |
| 10 | ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. , 2018, 59, 132. | | 20 |
| 11 | ERÎ ² alters the chemosensitivity of luminal breast cancer cells by regulating p53 function. Oncotarget, 2018, 9, 22509-22522. | 1.8 | 19 |
| 12 | Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis. Breast Cancer Research, 2017, 19, 79. | 5.0 | 20 |
| 13 | $ER\hat{i}^2$ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function. Oncotarget, 2016, 7, 13599-13611. | 1.8 | 39 |
| 14 | Pleiotropic signaling evoked by tumor necrosis factor in podocytes. American Journal of Physiology - Renal Physiology, 2015, 309, F98-F108. | 2.7 | 6 |
| 15 | ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway. Oncogene, 2015, 34, 4130-4141. | 5.9 | 45 |
| 16 | ERÎ ² Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling. Molecular Cancer Research, 2014, 12, 843-854. | 3.4 | 14 |
| 17 | ERβ1 represses basal-like breast cancer epithelial to mesenchymal transition by destabilizing EGFR. Breast Cancer Research, 2012, 14, R148. | 5.0 | 73 |